Navigation Links
BioMed Realty Trust and BIND Biosciences Sign New Lease at Vassar Street Property
Date:7/28/2011

Medicinal Nanoengineering® platform to develop and commercialize our best-in-class targeted therapeutics."

Alan D. Gold, Chairman and Chief Executive Officer of BioMed, remarked, "We welcome BIND Biosciences to Vassar Street and the vibrant Cambridgeport life science submarket. The company's co-founders and leaders, Dr. Robert Langer of MIT, Dr. Omid Farokhzad of Harvard, and Scott Minick, CEO, have quickly positioned BIND as a leader in the emerging field of nanomedicine. The newly redeveloped and redesigned Vassar Street facility will be the ideal home for BIND to pursue its pioneering research in nanomedicine and deploy their proprietary Medicinal Nanoengineerin® platform to accelerate targeted drug development."

About BIND Biosciences

BIND Biosciences, Inc. is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering® platform to produce best in class drugs. BIND's platform enables the design, engineering and manufacturing of targeted nanoparticle therapeutics with unprecedented control over drug PK, biodistribution and cell- or tissue-specific targeting. Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective, and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications, or life cycle extension for mid- and late-stage products. BIND's initial product development efforts are in the areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's lead program, BIND-014, targets a surface protein upregulated in a broad range of solid tumors.  BIND-014 is currently undergoing Phase I clinical testing in cancer patients.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate
'/>"/>

SOURCE BioMed Realty Trust, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
2. Regenesis Biomedical Announces Additions to Board of Directors
3. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
4. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
5. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
6. BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends
7. BioMed Realty Trust Announces Exercise of Over-Allotment Option
8. Isilon CTO Addresses Life Science Data Storage Challenges at Harvard Medical Schools BioMedical HPC Leadership Summit
9. BioMed Realty Trust Announces 36,900 Square Foot Lease in Seattle With Novo Nordisk
10. Balan Biomedical, Inc. Announces the Formation of Battery Consulting Group
11. Environmental Tectonics Corporations BioMedical Systems Division Places Two Monoplace Chambers at East Orange (NJ) General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)...   Kinaxis ®, provider of RapidResponse ®, a cloud-based ... planning ( S&OP ) service, is proud to be a ... be held at the Hilton San Diego Bayfront, January 30 ... Elisabeth Kaszas , Director of Supply Chain at Amgen, as ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 2011 Jennerex, Inc., a private clinical-stage biotherapeutics ... first-in-class targeted oncolytic virus products for cancer, together ... enrollment has been initiated and the first patient ... trial called TRAVERSE.  The trial is evaluating the ...
... BRISBANE, Calif., Nov. 3, 2011 InterMune, Inc. (NASDAQ: ... for the third quarter and nine months ended September ... clinical development activities, including the launch of Esbriet® (pirfenidone) ... Executive Officer and President of InterMune said, "The third ...
... 3, 2011 Reportlinker.com announces that a new ... Global Biochip Markets: Microarrays ... INTRODUCTION  ... BCC,s goal for this study was to determine ...
Cached Biology Technology:Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 2Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 3Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 4Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 5Jennerex Announces First Patient Randomized in Phase 2b Clinical Trial of JX-594 in Liver Cancer 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 2InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 3InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 4InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 5InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 6InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 7InterMune Reports Third Quarter 2011 Financial Results and Business Highlights 8Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Global Biochip Markets: Microarrays and Lab-on-a-Chip 5
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... anthrax detection cartridge developed at Sandia National Laboratories and ... easier, faster and cheaper. , Bacillus anthracis ... in soils all over the world and can cause ... animals. The bacteria can survive in harsh conditions for ... may occur through skin contact, inhalation of spores or ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... BIRMINGHAM, Ala. The U.S. Department of Energy (DOE) ... of Alabama at Birmingham (UAB) School of Engineering on ... the capture and permanent safe storage, or sequestration, of ... Southern Company, the parent company of Alabama Power. ...
... is publishing a special issue "Beyond the Origin: Charles ... of Species which was published 150 years ago in November ... Dr. Ulrich Kutschera, professor of plant physiology and evolutionary biology ... this special issue are available free of charge until 30 ...
... brilliance of butterfly wings has inspired a 3.2m, three-year ... fields of security, energy and the environment. The University ... signed a collaborative contract to develop new technologies based ... next three years a team of physicists from the ...
Cached Biology News:UAB, partners seek safe carbon dioxide storage for 'greener' power generation 2UAB, partners seek safe carbon dioxide storage for 'greener' power generation 3£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2
a1-Antitrypsin (human, alpha-1 AT)...
... vesicles are used to study co-translational ... Processing events such as signal peptide ... glycosylation can be examined by the ... vitro in the presence of these ...
... using Mo Bio luciferase assay. Mo Bio Laboratories ... will allow you to certify your products ATP-Free ... you to deliver them to your customers in ... limit is 3.5 x 10-12 /l, which will ...
... New Concept in Microarrays: Biomedical Photometrics Inc. ... GmbH (Jena, Germany) have collaborated to develop ... ArrayTube System. The DNAscope AT is ... new DNAscope AT automatically reads up to ...
Biology Products: